Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
The HELIOS-B trial demonstrates that vutrisiran significantly reduces mortality and cardiovascular events in ATTR-CM patients, with its efficacy unaffected by concurrent use of tafamidis or heart failure medications, supporting its broad th
This review synthesizes evidence on the prevalence and prognostic value of right ventricular dysfunction in ATTR-CM and the therapeutic impact of vutrisiran on RV function from the HELIOS-B trial, underscoring RV free wall strain as a key b
This article reviews the prognostic role of left atrial dysfunction in transthyretin amyloid cardiomyopathy and evaluates vutrisiran’s impact on atrial function and clinical outcomes based on a secondary analysis of the HELIOS-B phase 3 tri